Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?

Viking Therapeutics has sufficient cash reserves ($502M) to fund operations through 2028, with a key near-term catalyst in Q3 2026 when phase 1 maintenance trial data for its lead drug VK2735 will be released. This data could significantly impact investor sentiment regarding the company's dual-formulation strategy (subcutaneous injection followed by oral maintenance), though it's unlikely to derail the ongoing phase 3 trials. The trial results will inform dosing decisions for upcoming extension studies.